MindMed (NASDAQ: MNMD)

Last close As at 20/05/2024

USD8.13

−0.10 (−1.16%)

Market capitalisation

USD622m

MindMed is a US clinical-stage biopharmaceutical company leveraging novel psychedelic medicines to target mental health conditions. The company has programs for the treatment of conditions such as generalized anxiety disorder, attention deficit hyperactivity disorder, autism spectrum disorder and opioid use disorder.

Latest Insights

Healthcare | edison tv

MindMed update on major depressive disorder data: Rob Barrow, CEO

Healthcare | edison tv

MindMed – executive interview with Dan Karlin, CMO

Healthcare | edison tv

MindMed – executive interview with Rob Barrow, CEO

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Maxim Jacobs

    Vice President of Investor Relations and Corp

  • Robert Barrow

    CEO

  • Schond Greenway

    CFO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (6.4) 60.3 142.5
Relative (12.4) 50.2 91.5
52 week high/low US$11.8/US$2.4

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free